Abbott acquires Piramal's domestic formulations business for $3.7 billion
This article was originally published in Scrip
Executive Summary
Abbott has signed a definitive agreement to acquire Piramal Healthcare's domestic formulations business for an up-front payment of $2.12 billion and additional annual payments of $400 million for the next four years starting in 2011.
You may also be interested in...
India’s Piramal Pharma Rings The Bell On Domestic Stock Exchange Listings
Piramal Pharma is “embarking on a new journey as a focused pharma entity,” as it seeks to “identify and secure inorganic and organic growth opportunities to generate consistent shareholder value.”
Ransomware Attacks: The State Of Play As Indian Firms Mount Defense
Pharma continues to be targeted by cyber criminals – the latest being India’s top-ranked company, Sun Pharma. Experts highlight some of the key vulnerabilities and why firms need to prioritize cyber resilience.
What Pharma CEOs, PEs Want To Move The Innovation Needle In India
Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.